On top of the success of anti-CTLA-4 antibody, ipilimumab, and antibodies against PD-1 and PD-L1, trials combining both ipilimumab and nivolumab demonstrated encouraging results in advanced melanoma (2, 5). Here, CTLA4 is linked to melanoma.